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EVIDENCE BASED NEURO-ONCOLOGY
Prognostic value of 1p/19q chromosomal codeletion in patients with
oligodendroglioma
Altaf Ali Laghari, Muhammad Usman Khalid, Namra Qadeer, Muhammad Shahzad Shamim

Abstract
Oligodendrogliomas are common intra-axial primary
brain tumours, and carry special significance due to
several key features, which when present provide better
prognosis compared to other intra-axial tumours. One of
these features is presence of 1p/19q chromosomal codeletion that seems to not only be a marker of better
prognosis but also signifies better response to
chemotherapy. Herein the authors review the literature
for evidence of the prognostic value of 1p/19q codeletion in OD.
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Introduction
Oligodendrogliomas (OD) account for 10% of all gliomas
and 4% of all primary brain tumours.1 They are diffusely
infiltrating tumours, arising from the white matter of
cerebral hemispheres. These tumours characteristically
show better prognosis compared to most other gliomas,
especially in the presence of certain features such as
young age at presentation, good performance status at
presentation and after surgery, frontal location,and
combined loss of 1p/19q.2 1p/19q chromosomal codeletion seems to not only be a marker of better
prognosis but also signifies increased response to
adjuvant therapy with selective drugs.3,4 Longer
progression free survival (PFS) has been noted amongst
patients who had been treated for a confirmed 1p/19q codeleted OD, although improvement in overall survival
(OS) has not been definitively established. Genetic
analysis of these tumours is now recognized at the basis
for classification of tumour type, and for the prediction of
biological behaviour, and response to therapeutic
modalities. There is extensive literature and numerous
clinical trials exploring the relationship between
prognosis of OD with 1p/19q co-deletion. This review
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focuses on a few of these articles to provide a brief yet
holistic picture on the topic.

Review Of Evidence
As early as 2000, Smith et al., demonstrated that 1p/19q
chromosomal loss in pure OD was a statistically significant
indicator of prolonged survival.5 Cairncross et al. 6, did an
exhaustive research on 289 patients diagnosed with
anaplastic OD and their response to radiotherapy (RT)
alone compared to RT with procarbazine, lomustine, and
vincristine (PCV) chemotherapy with the conclusion that
PCV with RT did not prolong survival.6 Jenkins et al.,then
through sequencing and following up 119 patients,
predicted a better overall survival of approximately one
year for patients with low grade OD featuring 1p/19q codeletion or translocation, especially those who received
higher doses of RT.7 Van den Brent et al., also conducted a
major study in 2006 with a total of 368 patients with
anaplastic OD enrolled and followed up for a median of

Figure-1(a): MRI T1WI with contrast showing a heterogeneously enhancing
oligodendroglioma in right temporoparietal region.
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Figure-1(b): Post-operative MRI T1WI with contrast scan of the same patient showing
maximal safe resection.

60 months.8 Patients were either given 33 cycles of RT or
PCV with RT, OS was significantly higher in RT with PCV
therapy although 36% of patients had to discontinue PCV
due to toxicity. They concluded that although overall
survival was unchanged, progression-free survival was
significantly better in patients who had OD with 1p/19q
chromosomal co-deletion. In 2012 Yip et al., further
analyzed chromosomal mutations of 1p/19q and genes
encoding isocitrate dehydrogenase (IDH) as diagnostic
markers for ODs.9 Lecavalier-Barsoumet al., in 2014,
systematically reviewed treatment modalities for
anaplastic oligodendrogliomas with the aim of
establishing the predictive and prognostic value of
markers such as 1p/19q co-deletion.10 To this effect PCV
prior to RT increased mean overall survival, with the
subset of ODs with 1p/19q chromosomal codeletion
showing increased sensitivity to combined PCV with RT.
However, grade 3 and 4 toxicities were noted with PCV
therapy and a conclusive replacement with
temozolomide was unable to be ascertained. Li et al.,in
2014 again, studied and followed a 100 cases of OD and
were able to associate 1p/19q loss, as well as Sox-17
protein, to better prognosis.11 Sabha et al.,also
investigated a cohort of 108 non-enhancing hemispheric
grade II-III gliomas with results indicating that 1p/19q loss
was predictive of overall survival but not progression free
survival.12 Interestingly IDH mutation was shown to be
indicative of both and merits further studies. In 2016,

Hataet al.,retrospectively analyzed the long-term
outcome of a case series (36 patients) with OD treated
with RTand procarbazine, nimustine, vincristine (PAV)
therapy.3 Their results showed that IDH mutation and
1p/19q loss were the prognostic factors to consider for
OD, not WHO grade, furthermore there was a significantly
better prognosis for patients with 1p/19q co-deletion. In
2017 Hacisalihogluet al., followed through with a
retrospective analysis of 41 anaplastic OD cases, 35
patients received standard radiotherapy whilst 26
patients then underwent additional chemotherapy with
temozolomide.2 In the 19 patients who had chromosomal
1p/19 co-deletion, progression free survival was noted to
be significantly higher, regardless of treatment modality.
Lastly McNamraet al., did a retrospective analysis on 106
patients in 2017 to determine treatment outcomes in
patients diagnosed with gliomas with full or partial
1p/19q codeletion.13 Of these patients, 66% had full
1p/19q chromosomal co-deletion and these were found
to have better progression free survival than those with
no co-deletion or 1p or 19q codeletion alone. In addition
upfront therapy (in some cases with temozolamide alone)
was found to have prognostic value similar to 1p/19q codeletion.

Conclusion
Chromosomal codeletion of 1p/19q is predictive of a
favourable prognosis for patients regardless of treatment.
Presence of co-deletion however is particularly indicative
of sensitivity to PCV therapy, in conjunction with
radiotherapy. Temozolomide is a promising alternative to
PCV but as of this moment in time its efficacy compared
to PCV in OD with 1p/19q co-deletion is not well
established. In addition, studies seem split on whether
1p/19q loss provides better overall survival or progression
free survival though most studies do point towards the
latter.
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